Defective Drug Intake: How to Qualify Pharmaceutical Liability Cases on the First Call

Why Defective Drug Cases Start and End at the Intake Call

Pharmaceutical liability cases are among the most valuable in personal injury law. A single successful defective drug claim can be worth hundreds of thousands of dollars. Mass tort consolidations routinely settle for billions. And almost every one of them begins with a phone call where whoever picks up had no idea what they were walking into.

That first conversation is where defective drug cases are won or lost before an attorney ever opens a file. The caller does not say “I have a pharmaceutical products liability claim.” They say “I took [medication] and now I’m in the hospital” or “my husband died after they changed his blood pressure medication.” The intake conversation has to translate that into qualified, documented, actionable information fast, before the caller hangs up, talks to another firm, or stops believing anyone can help them.

This article covers exactly what needs to happen on that first call.

The Three Qualifiers Every Defective Drug Intake Must Establish

Before anything else, every defective drug intake must nail three facts. If any of the three is missing, the case is either unqualified or under-documented from the start.

1. Product-injury link

Did this person take a specific drug, and did they suffer a specific, documented injury that is plausibly connected to it? The connection does not need to be proven at intake. It needs to be plausible enough to send to an attorney. Get the drug name, the dosage if they know it, the injury or diagnosis, and the approximate timeline. “Started taking [drug] in March 2024, diagnosed with [injury] in August 2024” is a usable intake note. “They said a drug hurt them” is not.

2. Prescription or use history

Was this drug prescribed, or did they buy it over the counter? Who prescribed it and when? Do they still have the prescription records, pharmacy receipts, or bottles? Cases with documented prescription trails move faster. OTC drug cases are qualifiable too but require different documentation. The person on the phone needs to know where those records are before the call ends.

3. Statute of limitations viability

Pharmaceutical liability statutes of limitations vary by state and by the nature of the claim, but most are two to three years from discovery of the injury. “Discovery” is the critical word. A caller who was injured four years ago but only learned six months ago that their injury was drug-related may still be within the window. Do not dismiss a case because the injury sounds old. Get the date they first linked the injury to the drug, not just the injury date itself.

The Six Questions That Actually Qualify the Case

The goal of intake is not to conduct a deposition. It is to gather enough information for an attorney to make a go/no-go decision. These six questions do that without overwhelming a caller who is probably scared, sick, or grieving.

Question 1: “What was the name of the medication you were taking?”

Get it exactly. Ask them to spell it if needed. Ask if they still have the bottle so they can read it off the label. Generic and brand names both matter. If they cannot remember, ask what condition it was prescribed for, and document that instead. An attorney can work backward from a condition to likely drugs, but they cannot work with “some pill.”

Question 2: “What happened to you after you started taking it?”

Let them answer in their own words first. Then narrow it down: when did symptoms start, what were the symptoms, did they see a doctor, what was the diagnosis? You are looking for an injury or diagnosis that can be tied to a documented side effect or known defect in that drug. If they mention a diagnosis, document it verbatim, including the date they were diagnosed.

Question 3: “How long were you taking the medication before this happened?”

Timeline is everything in pharmaceutical liability. Some injuries emerge within weeks. Others take years of use to manifest. Some drugs have latency periods of a decade or more. A caller who says “I only took it for two weeks” is giving you a potentially different case than one who says “I was on it for five years.” Both can be valid. Both need to be documented accurately.

Question 4: “Are you still taking the medication?”

This matters for two reasons. First, if they are still taking the drug, there is a potential ongoing harm situation that changes the urgency. Second, if they stopped, when and why did they stop? Did a doctor tell them to stop because of a problem? Did they stop on their own after seeing news coverage? Stopping the medication because a doctor flagged a risk is a significant intake fact.

Question 5: “Have you seen a doctor about this, and do you have medical records?”

No documented medical treatment means no case, in most circumstances. The injury has to appear in the record. If they have not seen a doctor, the intake conversation needs to strongly encourage them to do so before the case can move forward. If they have seen doctors, get the names and approximate dates. Ask if they have received any diagnosis in writing.

Question 6: “Have you been contacted by anyone else about this medication, or seen anything in the news?”

This question tells you whether the case is part of a broader mass tort action, a class action, or a known drug-harm landscape. If the caller says they saw a TV commercial asking about people injured by a specific drug, that is a mass tort signal. Your firm needs to know whether it is handling the case independently or whether the caller should be referred to a consolidation, depending on your firm’s mass tort relationships.

What Makes Defective Drug Intake Different from Other Personal Injury Cases

Personal injury intake generally follows a predictable arc: event, injury, fault. Defective drug cases break that arc in three important ways that catch intake staff off guard.

The injury is often invisible at first

A car accident leaves a bruise, a fracture, a police report. A defective drug often leaves bloodwork, a diagnosis, a specialist’s note from months after the person started taking the medication. Callers may not have connected the drug to the injury until they saw news coverage or their doctor told them. Whoever handles the intake phone needs to listen for delayed-discovery language: “I didn’t know it was the drug until…” or “My doctor told me it might be related to…”

The manufacturer, not a person, is usually the defendant

In a car accident case, callers want to know who was at fault. In a defective drug case, most callers are confused about who they are even suing. The intake conversation may need to briefly explain that the case is against the company that made or marketed the drug, not their prescribing doctor. This affects how the caller describes the situation, what documents they have, and what insurance questions are even relevant.

Mass tort consolidations change the economics

If a specific drug is already in multi-district litigation or a class action, the case economics and intake process change significantly. Your intake system needs to flag known mass tort drugs by name. If the caller mentions one, the intake process needs to route that information differently than a standalone products liability claim.

The Intake Mistakes That Kill Pharmaceutical Liability Cases

These mistakes are not hypothetical. They happen on every high-volume intake line at some point.

Dismissing late callers too quickly

The most common intake mistake in defective drug cases is treating the injury date as the statute-of-limitations start date. As noted above, the clock often starts at discovery, not at the first symptom. A caller who was injured four years ago and just learned the drug was at fault may have a live case. The intake conversation needs to ask when they first connected the injury to the drug, not just when the injury occurred.

Failing to get the drug name and dosage

Vague drug references are worthless to an attorney doing the initial case review. “Some cholesterol medication” describes hundreds of drugs. “Atorvastatin 40mg prescribed by Dr. [Name] at [Clinic] starting in April 2023” gives an attorney something to work with immediately. The intake process has to push for specificity, and if the caller cannot provide it on the first call, there needs to be a clear callback plan to get it.

Not asking about other lawsuits

Has the caller already contacted another firm? Have they signed a retainer? Are they currently represented? This is not a minor administrative question. If they are already in litigation elsewhere or have signed representation agreements, that changes everything. The intake process has to ask directly.

Skipping the medical documentation question

A defective drug case without documented medical treatment is almost always dead on arrival. If whoever handles the intake phone skips the “do you have medical records” question because the caller seems credible, the firm is wasting follow-up time on cases that cannot move forward. Ask it every time.

What a Qualified Defective Drug Intake Note Looks Like

Here is the difference between an intake note that moves a case forward and one that buries it.

Unqualified note:
“Caller says they were hurt by a medication. Wants to speak to an attorney. Said they have been sick.”

Qualified note:
“Caller: [Name], [Phone]. Drug: Metformin 1000mg, prescribed by Dr. [Name] at [Clinic], started June 2022. Injury: Lactic acidosis diagnosis, hospitalized August 2022, documented by [Hospital]. First linked drug to injury: November 2023 after reading news article. Still has prescription records and discharge papers. No prior legal contact. Not currently represented. Callback scheduled for [Date/Time] to confirm medical records access.”

The second note gives an attorney everything needed to make a go/no-go decision in under sixty seconds. The first note requires a follow-up call to gather basic information that should have been captured on the first contact.

Handling the Emotional Layer

Defective drug callers are frequently in one of two emotional states: angry or exhausted. The angry caller has done research, is convinced they were harmed, and wants action. The exhausted caller has been sick for a long time, does not fully understand what happened to them, and needs someone to organize their situation for them.

Both callers require the same intake outcome but different tonal approaches. The angry caller needs to feel heard quickly so they stop talking over the questions. A brief acknowledgment (“I can see why you’re frustrated, and what you’re describing sounds like something we need to look into”) followed by structured questions works well. The exhausted caller needs to feel that someone is taking charge. Whoever picks up the phone should take the lead: “I am going to ask you a few specific questions so we can understand exactly what happened. Can we start with the medication name?”

What both callers cannot tolerate is vagueness or delay. “Someone will get back to you” without a specific callback time loses the case. The close of every defective drug intake call needs a specific next step with a specific time attached to it.

When to Escalate Immediately

Most defective drug intakes can follow a standard qualification flow. But a few situations warrant immediate attorney escalation, not a callback queue.

• The caller or a family member is currently hospitalized and the injury is actively progressing
• The caller says a family member died from the drug-related injury and they are a surviving spouse or parent
• The caller mentions a statute of limitations date that is within thirty days
• The drug named is part of a known mass tort action that your firm is actively participating in
• The caller is being pressured by a hospital billing department and does not understand their rights

These situations need an attorney, not a callback form. The intake process has to have a clear escalation path, and whoever handles the phone has to know when to use it without waiting for approval.

What to Do Next

If your intake process for defective drug cases feels uncertain or inconsistent, here is where to start:

1. Build a short-form defective drug intake script with the six questions above plus an escalation decision tree. One page, laminated if your team uses paper, loaded into your intake software if they use screens.
2. Create a list of current mass tort drugs to keep at the intake station. Update it quarterly. When a caller mentions a drug on that list, the routing changes.
3. Train your intake team on discovery-date doctrine for pharmaceutical cases. The single most common intake error is applying the wrong statute-of-limitations framework to drug injury cases.
4. Audit your last twenty defective drug intake notes against the qualified note standard above. How many have specific drug names, injury dates, discovery dates, and documentation status?
5. Set a callback standard for defective drug cases: specific time, specific contact, within twenty-four hours. Not “we’ll be in touch.”

The first call is the only call you are guaranteed to have with a pharmaceutical liability prospect. Build the intake process around that reality, and the cases that belong at your firm will stay there.